Developing A Therapeutic Strategy For Cystinotic Nephropathy With iPS Cells
CRF has supported Dr. Freedman since 2018, awarding $392,316 for his important study at the University of Washington Medicine/Nephrology, using human induced pluripotent stem (iPS) cells and derived kidney organoids to develop therapeutics for cystinotic nephropathy. His August 2020 report outlines the progress he has made towards the aims of the study. We are excited about his progress and the potential his work has for our cystinosis community. View the complete progress report.
Research Progress Update by Benjamin (Beno) Freedman, PhD,
